In this newly created position, Brandon will lead manufacturing and operations at the company's 183,000 square foot Department of Defense Advanced Development and Manufacturing facility in Alachua, Florida.
Prior to joining Ology Bioservices, Brega served in various positions at Merck and Co., most recently as Associate vice president, Plant Management at the company's Durham, North Carolina location the largest vaccines-only facility in Merck's network.
Prior to joining Merck, Brega worked for a number of animal health manufacturers including Pfizer Inc., Wyeth Pharmaceuticals, Boehringer Ingelheim and Merial Ltd., leading operations and technical organizations in the production of vaccines, biologics and sterile injectables.
He has broad base of experience with both drug substance and drug product manufacturing across both small and large molecules.
Brega holds both a Bachelor of Science in Biology and Master of Arts in Management from Doane University and earned a Masters Certification in Six Sigma and Lean Six Sigma Black Belt from Villanova University.
Ology Bioservices serves both government and commercial clients, specialising in biologic drug substance manufacturing, from early stage through commercial product.
The company has 183,000 square feet of manufacturing, process development and QA/QC space in its Department of Defense Advanced Development and Manufacturing Facility in Florida.
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Yuyu Pharma invests in Dalan Animal Health
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats